Publications by authors named "Nicolau Beckmann"

59Publications

Editorial for "Echo Time-Dependence of Observed Lung T1 in Patients With Cystic Fibrosis and Correlation With Clinical Metrics".

Authors:
Nicolau Beckmann

J Magn Reson Imaging 2020 12 3;52(6):1655-1656. Epub 2020 Jul 3.

Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
December 2020

Editorial for "Validation of Automated Perfusion-Weighted Phase-Resolved Functional Lung (PREFUL)-MRI in Patients With Pulmonary Diseases".

Authors:
Nicolau Beckmann

J Magn Reson Imaging 2020 07 14;52(1):115-116. Epub 2020 Feb 14.

Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, CH-4056, Basel, Switzerland.

View Article and Find Full Text PDF
July 2020

Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.

J Neuroimmunol 2018 05 3;318:103-113. Epub 2018 Mar 3.

Musculoskeletal Diseases, Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland. Electronic address:

View Article and Find Full Text PDF
May 2018

Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis.

Eur J Pharmacol 2017 Aug 12;809:64-72. Epub 2017 May 12.

Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland. Electronic address:

View Article and Find Full Text PDF
August 2017

Editorial: Imaging in Pharmacological Research.

Front Pharmacol 2016 3;7:511. Epub 2017 Jan 3.

Department of Radiology and Nuclear Medicine, VU University Medical Center Amsterdam, Netherlands.

View Article and Find Full Text PDF
January 2017

MRI as Primary End Point for Pharmacologic Experiments of Liver Regeneration in a Murine Model of Partial Hepatectomy.

Acad Radiol 2016 11 29;23(11):1446-1453. Epub 2016 Aug 29.

Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Forum 1, Novartis Campus, Fabrikstr. 28.3.07, CH-4056 Basel, Switzerland. Electronic address:

View Article and Find Full Text PDF
November 2016

Long-term distribution of biodegradable microparticles in rat muscle quantified noninvasively by MRI.

Magn Reson Med 2016 Apr 12;75(4):1736-42. Epub 2015 May 12.

Novartis Institutes for BioMedical Research, Analytical Sciences & Imaging, Basel, Switzerland.

View Article and Find Full Text PDF
April 2016

Imaging of cerebrovascular pathology in animal models of Alzheimer's disease.

Front Aging Neurosci 2014 13;6:32. Epub 2014 Mar 13.

Analytical Sciences and Imaging, Novartis Institutes for BioMedical Research Basel, Switzerland.

View Article and Find Full Text PDF
April 2014

Hyaluronidase modulates bleomycin-induced lung injury detected noninvasively in small rodents by radial proton MRI.

J Magn Reson Imaging 2015 Mar 13;41(3):755-64. Epub 2014 Mar 13.

Novartis Institutes for BioMedical Research, Analytical Sciences and Imaging, Basel, Switzerland; University of Basel, Biocenter, Basel, Switzerland.

View Article and Find Full Text PDF
March 2015

Adriamycin-induced nephropathy in rats: functional and cellular effects characterized by MRI.

J Magn Reson Imaging 2015 Mar 5;41(3):829-40. Epub 2014 Mar 5.

Novartis Institutes for BioMedical Research, Analytical Sciences and Imaging, Basel, Switzerland; University of Basel, Biocenter, Basel, Switzerland.

View Article and Find Full Text PDF
March 2015

Bleomycin-induced lung injury in mice investigated by MRI: model assessment for target analysis.

Magn Reson Med 2012 Feb 7;67(2):499-509. Epub 2011 Jun 7.

Global Imaging Group, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
February 2012

Optical and magnetic resonance imaging as complementary modalities in drug discovery.

Future Med Chem 2010 Mar;2(3):317-37

Novartis Institutes for Biomedical Research, Basel, Switzerland. sandanaraj.selvaraj@ novartis.com

View Article and Find Full Text PDF
March 2010

A view on imaging in drug research and development for respiratory diseases.

J Pharmacol Exp Ther 2011 May 11;337(2):335-49. Epub 2011 Feb 11.

Novartis Institutes for BioMedical Research, Clinical Imaging Group, Basel, Switzerland.

View Article and Find Full Text PDF
May 2011

Investigating pharmacology in vivo using magnetic resonance and optical imaging.

Drugs R D 2008 ;9(5):277-306

Institute for Electronic Structure and Laser, Foundation for Research and Technology-Hellas, Heraklion, Greece.

View Article and Find Full Text PDF
January 2009

Allergen-induced lung inflammation in actively sensitized mice assessed with MR imaging.

Radiology 2008 Sep 22;248(3):834-43. Epub 2008 Jul 22.

Respiratory Diseases Department, Novartis Institutes for BioMedical Research, Forum 1, Novartis Campus, WSJ-386.2.09, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
September 2008

Lung MRI for experimental drug research.

Eur J Radiol 2007 Dec 10;64(3):381-96. Epub 2007 Oct 10.

Discovery Technologies, Novartis Institutes for BioMedical Research, Lichtstr. 35, WSJ-386.2.09, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
December 2007

In vivo mouse imaging and spectroscopy in drug discovery.

NMR Biomed 2007 May;20(3):154-85

Discovery Technologies, Novartis Institutes for BioMedical Research, Lichtstrasse 35, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
May 2007

Non-invasive methods: investigation of airways diseases by MRI in rats.

ALTEX 2007 ;24 Spec No:12-5

Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.

View Article and Find Full Text PDF
November 2009

Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI.

Am J Physiol Lung Cell Mol Physiol 2007 Mar 3;292(3):L644-53. Epub 2006 Nov 3.

Discovery Technologies Department, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
March 2007

Macrophage infiltration detected at MR imaging in rat kidney allografts: early marker of chronic rejection?

Radiology 2006 Sep 12;240(3):717-24. Epub 2006 Jul 12.

Departments of Discovery Technologies and Transplantation Research, Novartis Institutes for BioMedical Research, Lichtstrasse 35, WSJ-386.2.09, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
September 2006

Identification with MRI of the pleura as a major site of the acute inflammatory effects induced by ovalbumin and endotoxin challenge in the airways of the rat.

Am J Physiol Lung Cell Mol Physiol 2006 Oct 25;291(4):L651-7. Epub 2006 May 25.

Novartis Institutes for BioMedical Research, Discovery Technologies, Lichtstr. 35, WSJ-386.2.09, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
October 2006

Evaluation of drug candidates: efficacy readouts during lead optimization.

Prog Drug Res 2005 ;62:185-255

Institute for Biomedical Engineering, University of Zurich/ETH Zurich, Switzerland.

View Article and Find Full Text PDF
January 2006

The pharmacological stimulation of NMDA receptors via co-agonist site: an fMRI study in the rat brain.

Neurosci Lett 2005 May 20-27;380(1-2):111-5. Epub 2005 Feb 9.

Departamento de Anatomia, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Av. Pau Brasil s/n, 21940-900 Rio de Janeiro, RJ, Brazil.

View Article and Find Full Text PDF
July 2005

Two-dimensional electrophoresis protein profiling and identification in rat bronchoalveolar lavage fluid following allergen and endotoxin challenge.

Proteomics 2004 Jul;4(7):2101-10

Novartis Institutes for Biomedical Research, Central Technologies-Analytical & Imaging Sciences Unit, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

Magnetic resonance imaging in biomedical research: imaging of drugs and drug effects.

Methods Enzymol 2004 ;385:240-56

Analytical and Imaging Sciences Unit, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

Magnetic resonance imaging in drug discovery: lessons from disease areas.

Drug Discov Today 2004 Jan;9(1):35-42

Novartis Institutes for BioMedical Research, Discovery Technologies, Analytics and Imaging Sciences Unit, Lichstr. 35, WSJ-386.209, CH-4002 Basel Switzerland.

View Article and Find Full Text PDF
January 2004

Effects of a mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging.

Eur J Pharmacol 2003 Dec;482(1-3):319-24

Discovery Technologies Center, Novartis Institutes for BioMedical Research, Lichstr. 35, WSJ-386.2.09, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
December 2003

Techniques: magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs.

Trends Pharmacol Sci 2003 Oct;24(10):550-4

Discovery Technologies Center, Novartis Institutes for BioMedical Research, Lichtstrasse 35, WSJ-386.2.09, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
October 2003

Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging.

Br J Pharmacol 2003 Sep 18;140(2):239-46. Epub 2003 Aug 18.

Novartis Institutes for Biomedical Research, Central Technologies, Analytics and Imaging Sciences Unit, Lichtstr. 35, WSJ-386.2.09 CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
September 2003

Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis.

Magn Reson Med 2003 Jun;49(6):1047-55

Central Technologies, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
June 2003

Noninvasive detection of endotoxin-induced mucus hypersecretion in rat lung by MRI.

Am J Physiol Lung Cell Mol Physiol 2002 Jul;283(1):L22-30

Central Technologies, Novartis Pharma, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2002

Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats.

Biochem Biophys Res Commun 2002 Mar;292(1):216-21

Central Technologies, Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2002